concurrent chemoradiotherapy with docetaxel cisplatin and 5fluorouracil tpf in patients with locally advanced squamous cell carcinoma of the head and neck objective compared with radiotherapy alone concurrent chemoradiotherapy significantly improves survival rates for patients with squamous cell carcinoma of the head and neck the aim of this study was to retrospectively evaluate the efficacy toxicity and longterm prognosis of concurrent chemoradiotherapy with docetaxel cisplatin and 5fluorouracil chemotherapymethods a total of 140 patients were enrolled and evaluated patients were received two cycles of docetaxel cisplatin and 5fluorouracil chemotherapy docetaxel 50 mgm2 day 1 cisplatin 60 mgm2 day 4 and continuous 5fluorouracil 600 mgm2day days 15 during definitive radiotherapyresults the overall response rate was 971 the 3 and 5year overall survival rates were 833 and 792 respectively the 3 and 5year diseasespecific survival rates were 842 and 800 respectively among patients with laryngeal or hypopharyngeal carcinoma the 5year laryngectomyfree survival rate was 649conclusions concurrent chemoradiotherapy with docetaxel cisplatin and 5fluorouracil showed excellent survival and organ preservation rates for the patients with locally advanced squamous cell carcinoma of the head and neck